These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 29303526)

  • 1. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
    Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternative mechanism of action of the DNP Pt
    Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
    Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
    Dai Y; Zhu Y; Cheng J; Shen J; Huang H; Liu M; Chen Z; Liu Y
    Chem Commun (Camb); 2020 Nov; 56(90):14051-14054. PubMed ID: 33103676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
    Zheng YR; Suntharalingam K; Johnstone TC; Yoo H; Lin W; Brooks JG; Lippard SJ
    J Am Chem Soc; 2014 Jun; 136(24):8790-8. PubMed ID: 24902769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C; Babu T; Kostrhunova H; Timm A; Basu U; Ott I; Gandin V; Brabec V; Gibson D
    J Med Chem; 2021 Aug; 64(15):11364-11378. PubMed ID: 34342437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
    Reshetnikov V; Arkhypov A; Julakanti PR; Mokhir A
    Dalton Trans; 2018 May; 47(19):6679-6682. PubMed ID: 29708261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oxaliplatin(iv) prodrug-based supramolecular self-delivery nanocarrier for targeted colorectal cancer treatment.
    Lim WQ; Phua SZF; Chen H; Zhao Y
    Chem Commun (Camb); 2018 Nov; 54(90):12762-12765. PubMed ID: 30370905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z; Hu W; Wang Z; Gou S
    Eur J Med Chem; 2017 Dec; 141():211-220. PubMed ID: 29031068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant Pt
    Norman DJ; Gambardella A; Mount AR; Murray AF; Bradley M
    Angew Chem Int Ed Engl; 2019 Oct; 58(40):14189-14192. PubMed ID: 31397963
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lee VEY; Lim ZC; Chew SL; Ang WH
    Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
    Qin X; Fang L; Zhao J; Gou S
    Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maleimide-functionalised platinum(IV) complexes as a synthetic platform for targeted drug delivery.
    Pichler V; Mayr J; Heffeter P; Dömötör O; Enyedy ÉA; Hermann G; Groza D; Köllensperger G; Galanksi M; Berger W; Keppler BK; Kowol CR
    Chem Commun (Camb); 2013 Mar; 49(22):2249-2251. PubMed ID: 23396381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
    Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
    Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.